Rafael (NYSE:RFL - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Friday.
Rafael Stock Up 0.8%
Shares of Rafael stock traded up $0.01 on Friday, reaching $1.34. 100,087 shares of the stock were exchanged, compared to its average volume of 102,824. Rafael has a twelve month low of $1.28 and a twelve month high of $3.19. The firm has a market capitalization of $47.06 million, a price-to-earnings ratio of -1.43 and a beta of 0.89. The business has a 50 day moving average price of $1.74 and a two-hundred day moving average price of $1.73.
Rafael (NYSE:RFL - Get Free Report) last released its earnings results on Wednesday, June 11th. The company reported ($0.19) EPS for the quarter. Rafael had a negative return on equity of 24.75% and a negative net margin of 3,127.60%.The firm had revenue of $0.36 million for the quarter.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of RFL. Wealth Enhancement Advisory Services LLC purchased a new position in Rafael during the first quarter valued at approximately $26,000. Ieq Capital LLC purchased a new position in Rafael during the first quarter valued at approximately $447,000. Simplex Trading LLC purchased a new position in Rafael during the second quarter valued at approximately $32,000. Americana Partners LLC purchased a new position in Rafael during the second quarter valued at approximately $76,000. Finally, Geode Capital Management LLC raised its position in Rafael by 72.9% during the second quarter. Geode Capital Management LLC now owns 451,139 shares of the company's stock valued at $781,000 after acquiring an additional 190,179 shares in the last quarter. 11.30% of the stock is currently owned by hedge funds and other institutional investors.
About Rafael
(
Get Free Report)
Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.
Featured Articles
Before you consider Rafael, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rafael wasn't on the list.
While Rafael currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here

We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.